# Evaluation of Third-line cART Regimen in Cambodia (3DICAM)

> **NCT03602690** · PHASE2 · UNKNOWN · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 54 (estimated)

## Conditions studied

- HIV/AIDS

## Interventions

- **DRUG:** Dolutegravir + Darunavir/ritonavir + optimized NRTI

## Key facts

- **NCT ID:** NCT03602690
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-04
- **Primary completion:** 2022-04-11
- **Final completion:** 2022-04-11
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2021-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602690, "Evaluation of Third-line cART Regimen in Cambodia (3DICAM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03602690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*